Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New antibody WIN378 aims to tame COPD lung inflammation

NCT ID NCT07646587

Disease control Sponsor: Windward Bio Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Sep 16, 2026 · Updated 2 times

Summary

This phase 2 trial is testing a new medicine called WIN378 for people with moderate to severe COPD. WIN378 is a long-acting antibody that blocks a protein involved in lung inflammation. The study will test different doses in 105 adults who are former smokers and already on standard triple therapy, to see if it is safe and helps control COPD.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
WIN378 (a long-acting antibody that blocks a protein called TSLP to reduce lung inflammation)
What this could lead to
If successful, this could lead to a new, longer-lasting treatment option for people with moderate to severe COPD, helping to control symptoms and reduce flare-ups.
What could go wrong
This is an early phase 2 trial with only 105 participants, so results may not apply to everyone. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

About 105 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

40 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 40 to 80 years * Post-BD spirometry at screening FEV1/FVC \< 0.70 and FEV1 30-80% predicted * On stable triple inhaled therapy (ICS/LABA/LAMA) for ≥ 3 months * Former smoker (≥ 10 pack-year history) and abstinence from smoking for ≥ 6 months * Elevated eosinophil count * Weight/BMI within allowed range Exclusion Criteria: * Clinically significant pulmonary disease other than chronic obstructive pulmonary disease (COPD) * Clinically significant comorbid medical conditions or infections that, in the investigator's judgment, could affect participant safety or interfere with study conduct * Clinically significant cardiovascular disease * Recent respiratory infection or COPD exacerbation * Exposure to approved or experimental biologic therapies for COPD with less than 5 half-life washout period * Pregnancy or breastfeeding * Smoking or diagnosed substance use disorder * Any condition or circumstance that, in the investigator's opinion, would make participation unsafe or compromise study integrity

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COPD (chronic obstructive pulmonary disease) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic obstructive pulmonary disease COPD, severe early onset Inflammation Respiration Disorders

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

COPD (chronic obstructive pulmonary disease)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    21 sites in 2 countries. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • WB Contracted Clinical Research Site

    RECRUITING

    Los Angeles, California, 93534, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    Miami Lakes, Florida, 33014, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    North Dartmouth, Massachusetts, 02747, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    Charlotte, North Carolina, 28277, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    Medford, Oregon, 97504, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    DuBois, Pennsylvania, 15801, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    McKinney, Texas, 75069, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    Waxahachie, Texas, 75165, United States

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1023AAB, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1028AAP, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1122AAK, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1425BEN, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C1425FVH, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires, C142ABP, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1414AIF, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Buenos Aires F.D., C1426ABP, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Buenos Aires, Mendoza Province, M5500AXR, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Mendoza, Mendoza Province, M5500CBA, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Rosario, Santa Fe Province, S2000KZD, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Rosario, Santa Fe Province, S2013OJN, Argentina

  • WB Contracted Clinical Research Site

    RECRUITING

    Santa Fe, Santa Fe Province, S3000ASF, Argentina

More trials for these conditions

Other studies related to the condition(s) this trial covers.